TY - JOUR
T1 - A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology
AU - Cranmer , Holly
AU - Shields, Gemma
AU - Bullement, Ash
PY - 2020/7/16
Y1 - 2020/7/16
N2 - Aims: To construct and compare a partitioned-survival analysis (PartSA) and a semi-Markov multi-state model (MSM) to investigate differences in estimated cost effectiveness of a novel cancer treatment from a UK perspective.
Materials and Methods: Data from a cohort of late-stage cancer patients (N > 700) enrolled within a randomised, controlled trial were used to populate both modelling approaches. The statistical software R was used to fit parametric survival models to overall survival (OS) and progression-free survival (PFS) data to inform the PartSA (package ‘flexsurv’). The package ‘mstate’ was used to estimate the MSM transitions (permitted transitions: (T1) ‘progression-free’ to ‘dead’, (T2) ‘post-progression’ to ‘death’, and (T3) ‘pre-progression’ to ‘post-progression’). Key costs included were treatment-related (initial, subsequent, and concomitant), adverse events, hospitalizations and monitoring. Utilities were stratified by progression. Outcomes were discounted at 3.5% per annum over a 15-year time horizon.
Results: The PartSA and MSM approaches estimated incremental cost-effectiveness ratios (ICERs) of £342,474 and £411,574, respectively. Scenario analyses exploring alternative parametric forms provided incremental discounted life-year estimates that ranged from +0.15 to +0.33 for the PartSA approach, compared with -0.13 to +0.23 for the MSM approach. This variation was reflected in the range of ICERs. The PartSA produced ICERs between £234,829 and £522,963, whereas MSM results were more variable and included instances where the intervention was dominated and ICERs above £7 million (caused by very small incremental QALYs).
Limitations and Conclusions: Structural uncertainty in economic modelling is rarely explored due to time and resource limitations. This comparison of structural approaches indicates that the choice of structure may have a profound impact on cost-effectiveness results. This highlights the importance of carefully considered model conceptualization, and the need for further research to ascertain when it may be most appropriate to use each approach.
AB - Aims: To construct and compare a partitioned-survival analysis (PartSA) and a semi-Markov multi-state model (MSM) to investigate differences in estimated cost effectiveness of a novel cancer treatment from a UK perspective.
Materials and Methods: Data from a cohort of late-stage cancer patients (N > 700) enrolled within a randomised, controlled trial were used to populate both modelling approaches. The statistical software R was used to fit parametric survival models to overall survival (OS) and progression-free survival (PFS) data to inform the PartSA (package ‘flexsurv’). The package ‘mstate’ was used to estimate the MSM transitions (permitted transitions: (T1) ‘progression-free’ to ‘dead’, (T2) ‘post-progression’ to ‘death’, and (T3) ‘pre-progression’ to ‘post-progression’). Key costs included were treatment-related (initial, subsequent, and concomitant), adverse events, hospitalizations and monitoring. Utilities were stratified by progression. Outcomes were discounted at 3.5% per annum over a 15-year time horizon.
Results: The PartSA and MSM approaches estimated incremental cost-effectiveness ratios (ICERs) of £342,474 and £411,574, respectively. Scenario analyses exploring alternative parametric forms provided incremental discounted life-year estimates that ranged from +0.15 to +0.33 for the PartSA approach, compared with -0.13 to +0.23 for the MSM approach. This variation was reflected in the range of ICERs. The PartSA produced ICERs between £234,829 and £522,963, whereas MSM results were more variable and included instances where the intervention was dominated and ICERs above £7 million (caused by very small incremental QALYs).
Limitations and Conclusions: Structural uncertainty in economic modelling is rarely explored due to time and resource limitations. This comparison of structural approaches indicates that the choice of structure may have a profound impact on cost-effectiveness results. This highlights the importance of carefully considered model conceptualization, and the need for further research to ascertain when it may be most appropriate to use each approach.
U2 - 10.1080/13696998.2020.1796360
DO - 10.1080/13696998.2020.1796360
M3 - Article
SN - 1369-6998
JO - Journal of Medical Economics
JF - Journal of Medical Economics
ER -